Back to top
more

Genocea Biosciences, Inc. (GNCA)

(Delayed Data from NSDQ)

$2.19 USD

2.19
83,256

-0.02 (-0.90%)

Updated Dec 13, 2019 03:56 PM ET

Add to portfolio

2-Buy   2      

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.63%
17.80%
9.42%
5.10%
2.04%
10.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value | F Growth | B Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Brokerage Reports

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Research for GNCA

 

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

0 items in cart

Genocea Biosciences, Inc. [GNCA]

Reports for Purchase

Showing records 1 - 20 ( 21 total )

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 1

11/11/2019

Company Report

Pages: 9

SITC ATLAS Data Should Create Shockwaves Across Neoantigen Field; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 2

10/24/2019

Company Report

Pages: 6

3Q19 Results; GEN-009 Update at SITC Then Quickly Look to Part B Update in Mid-2020

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 3

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for GNCA

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 4

09/30/2019

Company Report

Pages: 8

Early Clinical Promise Continues for ATLAS

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 5

07/25/2019

Company Report

Pages: 7

2Q19 Results; More Data Coming at ESMO''19; Target Adjusted to $32

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 6

06/24/2019

Industry Report

Pages: 19

Our Thoughts Post CAR-T and the Rise of the Cellicon Valley Summit

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 50.00

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 7

06/03/2019

Company Report

Pages: 10

Greatly Anticipated GEN-009 Immunogenicity Data Shine at ASCO; Target Increased to $42

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 8

05/16/2019

Daily Note

Pages: 6

First Exciting Tease for GEN-009 Immunogenicity; First Clinical Validation of ATLAS'' Neoantigen Vaccine at ASCO

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 9

04/30/2019

Company Report

Pages: 7

1Q19 Results; ASCO Should Be Exciting With First GEN-009 Immunogenicity Data; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 10

04/03/2019

Daily Note

Pages: 4

ATLAS Shows the Way to Clinically Meaningful Neoantigens; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 11

02/28/2019

Company Report

Pages: 7

2018 Results; Looking for ATLAS to Deliver First Clinical Validation Soon; Target Upped to $5.75

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 12

01/02/2019

Daily Note

Pages: 7

Part A Enrolled and Timelines Tightened; Driving Toward GEN-009 Differentiation; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 13

11/27/2018

Company Report

Pages: 7

KOL Event Highlights Critical Importance of Selecting Right Neoantigens; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 14

11/12/2018

Company Report

Pages: 13

All Neoantigen Roads Lead to ATLAS; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 50.00

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 15

11/06/2018

Daily Note

Pages: 6

SITC Teaser of Possible Breakthrough ATLAS Discovery

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 16

11/01/2018

Company Report

Pages: 6

3Q18 Results; Expect ATLAS'' Shoulders to get Broader at SITC

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 17

08/02/2018

Company Report

Pages: 6

2Q18 Results; ATLAS and GEN-009 Visibility Increasing

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 18

05/10/2018

Company Report

Pages: 6

1Q18 Results; Awaiting IND Clearance Followed by GEN-009 Manufacturing and Study Start

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 19

04/30/2018

Daily Note

Pages: 6

GEN-009 IND Filed; The Drive Towards Initial Data Begins

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 20

04/19/2018

Company Report

Pages: 10

ATLAS Neoantigen Selection Process Further Differentiates as IND Nears for GEN-009

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party